Get the Stockscreener App
5.88
5.33%
-0.31
Galectin Therapeutics Inc stock is traded at $5.88, with a volume of 88,629.
It is down -5.33% in the last 24 hours and up +17.43% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$6.19
Open:
$6.14
24h Volume:
88,629
Relative Volume:
0.27
Market Cap:
$399.09M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-8.0548
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+0.51%
1M Performance:
+17.43%
6M Performance:
+340.60%
1Y Performance:
+112.70%
1-Day Range:
$5.80
$6.29
1-Week Range:
$5.10
$6.32
52-Week Range:
$0.726
$6.55
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
5.80 | 399.09M | 0 | -45.08M | -33.68M | -0.73 |
|
ARGX
Argen X Se Adr
|
920.69 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
201.80 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.81 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
354.57 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
708.62 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
How Galectin Therapeutics Inc. stock reacts to Fed rate cutsWeekly Trend Report & Safe Swing Trade Setups - newser.com
Will Galectin Therapeutics Inc. (PHPN) stock beat international competitionWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
How Galectin Therapeutics Inc. (PHPN) stock trades pre earningsJuly 2025 Drop Watch & Daily Market Momentum Tracking - newser.com
How robust is Galectin Therapeutics Inc. (PHPN) stock financial positionGap Up & Real-Time Buy Signal Alerts - newser.com
Will Galectin Therapeutics Inc. (PHPN) stock hit analyst forecastsBond Market & Fast Gain Swing Trade Alerts - newser.com
How big funds are accumulating Galectin Therapeutics Inc. (PHPN) stock2025 Macro Impact & Low Drawdown Investment Strategies - newser.com
What sentiment indicators say about Galectin Therapeutics Inc. stock2025 Price Momentum & AI Based Trade Execution Alerts - newser.com
Galectin Therapeutics (NASDAQ:GALT) Insider Sells 121,117 Shares - MarketBeat
Can Galectin Therapeutics Inc. (PHPN) stock double in coming yearsWeekly Gains Report & Verified Swing Trading Watchlist - newser.com
Galectin Therapeutics (NASDAQ:GALT) Releases Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Can you recover from losses in Galectin Therapeutics Inc.Weekly Stock Summary & Entry Point Confirmation Signals - newser.com
Applying Elliott Wave Theory to Galectin Therapeutics Inc.July 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com
Will Galectin Therapeutics Inc. (PHPN) stock beat growth indexesWeekly Volume Report & Free AI Powered Buy and Sell Recommendations - newser.com
Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Galectin Therapeutics Reports Q3 2025 Financials - TipRanks
Galectin Therapeutics Insider Sold Shares Worth $662,510, According to a Recent SEC Filing - MarketScreener
Officer Jamil Sells 121,117 ($662.5K) Of Galectin Therapeutics Inc [GALT] - TradingView
Can Galectin Therapeutics Inc. (PHPN) stock sustain margin levelsJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Galectin Therapeutics Narrows Losses While Awaiting FDA Feedback - Finimize
Galectin Therapeutics (GALT) Strengthens Belapectin's Profile wi - GuruFocus
Galectin Therapeutics Reports Financial Results and NAVIGATE Trial Update Highlighting Belapectin's Antifibrotic Potential in MASH Cirrhosis - Quiver Quantitative
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update - The Manila Times
Galectin Therapeutics Q3 loss narrows - MarketScreener
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
How risky is Galectin Therapeutics Inc. stock nowPortfolio Profit Report & Daily Chart Pattern Signals - Fundação Cultural do Pará
What drives Galectin Therapeutics Inc PHPN stock priceAnalyst Downgrades & Minimal Investment Capital Gains - earlytimes.in
Officer Jamil Files To Sell 121,117 Of Galectin Therapeutics Inc [GALT] - TradingView
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Nov 13 '25 |
Sale |
5.47 |
121,117 |
662,510 |
4,479 |
0.31%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):